LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Invus
BioCentury
|
Apr 4, 2025
Finance
Isomorphic’s $600M funding among four megarounds: Finance Report
Other nine-digit financings go to Airna, Atsena, Neurona
Read More
BioCentury
|
Mar 5, 2025
Emerging Company Profile
Bambusa: Combining validated I&I targets in bispecifics to broaden efficacy
With $105M in venture funding, Bambusa has moved quickly towards the clinic with bispecifics in-licensed from antibody powerhouse Biotheus
Read More
BioCentury
|
Feb 20, 2025
Finance
Bambusa’s $90M series A; Recursion-backed accelerator’s ‘pre-seed’ fund: Venture Report
Plus fundings around the globe for Eg 427, Atrandi and Reverb
Read More
BioCentury
|
Dec 20, 2024
Emerging Company Profile
City: Taking RNAi beyond the liver
Maraganore’s latest RNA company pairs targeting tech with trigger molecules a fraction of the size of Alnylam’s
Read More
BioCentury
|
Dec 19, 2024
Emerging Company Profile
Ottimo: Differentiating from the VEGF bispecific pack via VEGFR-2
Newco, led by ex-Seagen CEO Epstein, announces $140M series A
Read More
BioCentury
|
Dec 13, 2024
Finance
Techbio VC Dimension upsizes for $500M second fund; PE firm takes stake in Andera
In BioCentury’s Venture Report: Fundings for Citryll, Angitia, Tasca, Veradermics and more
Read More
BioCentury
|
Oct 19, 2024
Finance
Cash raises for Inventiva, Akeso, Capricor
Public Equity Report: French biotech to fund MASH study with €348M lifeline; bispecifics developer raises $250; DMD cardiomyopathy play prices follow-on
Read More
BioCentury
|
Oct 11, 2024
Finance
City is location of Maraganore’s next RNAi play
BioCentury’s latest Venture Report includes rounds for Judo, Purespring, Basecamp, Arda and more
Read More
BioCentury
|
Aug 15, 2024
Finance
Venture Report: Halda bringing RIPTACs into clinic with crossover round
Plus: Abata draws strategic investment from BMS as it preps first human study in multiple sclerosis
Read More
BioCentury
|
Jul 18, 2024
Finance
Venture Report: Five biotechs raise nearly $800M in two-day flurry
Plus: New capital for CytoReason, Truvian and Renalys
Read More
Items per page:
10
1 - 10 of 212
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa
Help